Title:

Therapeutic and market expectancy of recombinant medicines

Subtitle:

Therapeutic and market expectancy of recombinant medicines

Creator:

Jarecka, Maria ; Borowicz, Piotr

Publisher:

Committee on Biotechnology PAS ; Institute of Bioorganic Chemistry PAS

Date issued/created:

2005

Subject and Keywords:

biotechnology

Abstract:

Therapeutic applications and global market of commercialized biopharmaceuticals-recombinant medicines have been presented. The first and second generation of genetically engineered products such as: hormones, cytokines, blood factors, monoclonal antibodies and others approved to date or undergoing clinical investigations in the US and EU have been described. They are used to treat or prevent many diseases, including: diabetes, growth deficiency, anemia, cardio-vascular disorders and, especially, immune-mediated inflammatory disorders and various cancers. The authors have also presented current global biopharmaceutical market, leading biopharmaceuticals, the fastest growing recombinant protein categories and strategic market analysis and forecasts until 2010.

Relation:

Biotechnologia, vol.71, 4 (2005)-.

Volume:

71

Issue:

4

Start page:

7

End page:

27

Resource type:

Text

Detailed Resource Type:

Article

Format:

application/pdf

Resource Identifier:

0860-7796 ; IChB B-67

Source:

Library of Institute of Bioorganic Chemistry PAS

Language:

pol

Language of abstract:

eng

Temporal coverage:

1988-2010

Rights:

Creative Commons Attribution BY-SA 4.0 license

Terms of use:

Copyright-protected material. [CC BY-SA 4.0] May be used within the scope specified in Creative Commons Attribution BY-SA 4.0 license, full text available at:

Digitizing institution:

Institute of Bioorganic Chemistry of the Polish Academy of Science

Original in:

Institute of Bioorganic Chemistry of the Polish Academy of Science

Projects co-financed by:

Operational Program Digital Poland, 2014-2020, Measure 2.3: Digital accessibility and usefulness of public sector information; funds from the European Regional Development Fund and national co-financing from the state budget.

Access:

Open